Oligonucleotides: The Next Wave of Manufacturing Processes

5

June

  • 3PM London / 10AM New York
  • Free
  • Why attend?
  • Speakers
  • Contact Us

Why attend?

For innovators in oligonucleotide therapy and conjugation, scaling from the lab to clinic will come with challenges. That’s because, whilst the therapeutic potential of oligonucleotides is considerable, common manufacturing processes are unsustainable. Furthermore, manufacturing centres are limited around the world.

What could transform production processes is CPI’s new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland. In this webinar, we learn more about the innovative ways in which this specialist facility is changing oligos manufacturing and what it could mean for future production methods.

We’ll also hear more about the Scottish expertise in oligonucleotides that is rapidly developing, supported by industry partnerships, and the country’s world-renowned universities.

GlobalData analysis will highlight the existing industry oligos landscape and the limitations of existing global production techniques.

Key learnings:

  • The key challenges with oligonucleotide manufacturing and why it needs to change
  • What new oligo production techniques you need to be prepared for
  • Innovations to improve sustainability and reduce manufacturing costs
  • Talent and expertise available in Scotland dedicated to supporting oligonucleotide research, development and manufacturing

Speakers

Select a speaker to learn more

Back
Barrie Cassey
Technology Lead, CPI

Having joined MMIC in 2021, Barrie has responsibility for creating and delivering their portfolio of innovation projects, including clinical trial supply, continuous direct compression, and oligonucleotide manufacturing Grand Challenges.

Prior to MMIC, he spent 21 years working for GSK in pharmaceutical manufacturing, mostly in technical leadership roles, including over 10 years as Technical Director at a manufacturing site.

Barrie has a BSc in Biotechnology from the University of Birmingham and PhD from the University of Sheffield.

Next speaker
Back
Claire MacLeod
Grand Challenge Lead - MMIC, CPI

Claire graduated with an MEng in Chemical Engineering and went on to complete a PhD on the topic of heterogeneous catalysis for Biodiesel production. She then spent 13 years working in various process development roles at AstraZeneca including specialisations in filtration and continuous processing. From there, Claire moved to CPI’s Medicines Manufacturing Innovation Centre where she is now the Oligonucleotides Grand Challenge Lead, managing a portfolio of projects including Grand Challenge 3 – Sustainable and Scalable Oligonucleotide Manufacturing.

Next speaker
Back
Eleni Tokali
Drug Intelligence Analyst, GlobalData

Eleni Tokali, MPharm, MPH, is a Drug Intelligence Analyst at GlobalData. Her primary responsibilities include managing and maintaining GlobalData’s Drugs Database, analyzing drug pipeline information and producing analytical market insight reports. Additionally, Eleni provides timely client support and performs database quality checks. Prior to joining GlobalData, Eleni worked as a registered pharmacist under the General Pharmaceutical Council (GPhC). Eleni has a firm knowledge of pharmaceutical industry dynamics as well as global public health perspectives. Eleni holds a Master of Pharmacy from the University of Brighton and a Master of Public Health from King's College London.

Next speaker

Enquiry